CEO Siu Wing Fung Executes Massive Insider Buy at 52‑Week Low, Signaling Bold Confidence in NewGenIVF’s Future Outlook

Insider Buying Signals a Bold Confidence in NewGenIVF’s Upside

On October 5, 2026, Chairman & CEO Siu Wing Fung Alfred executed a sizeable purchase of 139,811 Class B ordinary shares—an exercise of vested options under the company’s 2024 Share Incentive Plan. The transaction, reported at a price of $0.00 per share (reflecting the exercise price), increased his holdings to 146,132 shares, a jump of roughly 25 % over the previous month’s balance. The buy coincided with a modest market move: the stock closed at $0.11 on the previous day, a 36.8 % gain over the week but a staggering 91.1 % drop from the month‑earlier level. Despite the low nominal price, the action signals confidence from the top executive at a time when the share is trading near its 52‑week low of $0.064.

What This Means for Investors

Siu’s acquisition arrives after a pattern of consistent option exercises and share purchases throughout 2026, suggesting a long‑term commitment rather than a speculative play. When a CEO expands his personal stake—particularly after a reverse‑split and a best‑efforts offering—the market often interprets it as a vote of confidence in the company’s strategic trajectory. The fact that the buy was executed at the exercise price, not at market value, means it could be viewed as a “back‑to‑market” move that reduces dilution risk for existing shareholders. Investors may see this as a green flag that the leadership believes the company’s valuation will recover from the steep quarterly decline, especially as NewGenIVF has recently converted convertible notes and accessed an equity line of credit to fund growth initiatives.

The CEO’s Insider Profile

Alfred’s transaction history paints the picture of a CEO who actively leverages employee‑share plans to align his incentives with shareholders. From early May to early October 2026, he has exercised options totaling more than 500,000 shares, consistently increasing his holdings. His latest buy of 139,811 shares is the largest single transaction in the past two months, underscoring a surge in personal equity exposure. Historically, the CEO has preferred to lock in gains by exercising options before market volatility erodes potential upside, a strategy that has kept his ownership base robust even as the share price fluctuated. This pattern indicates a risk‑averse yet opportunistic stance: he locks in value when it is low and refrains from selling, suggesting confidence that the company’s fundamentals will strengthen.

Company‑Wide Insider Activity in Context

While Siu’s move dominates the headlines, other senior executives have also been active. Chief Marketing Officer Tina Fong Hei Yue purchased 139,811 shares on the same day, mirroring the CEO’s strategy. Across the board, insiders have been buying rather than selling, hinting at a broader belief in the company’s prospects. The lack of large sales by key insiders mitigates concerns that the company is preparing for an imminent downturn, and the recent uptick in buzz—over 700 %—combined with a positive sentiment (+11) suggests that investor chatter is increasingly favorable.

Outlook for NewGenIVF

With a market cap of just $311 k and a price‑earnings ratio of 0.05, NewGenIVF remains a high‑risk, high‑reward play in the biotech niche. The CEO’s substantial share purchase, coupled with the company’s recent capital‑raising activities, could be the first step toward a resurgence in investor confidence. For investors, the insider buying spree offers a signal that those with the most information are betting on upside. However, the stock’s volatile history and the company’s limited disclosed financials warrant caution. A prudent strategy would involve monitoring the company’s upcoming earnings, pipeline milestones, and any further insider transactions, while remaining mindful of the thin liquidity and low share price that could amplify price swings.